ARICEPT Safety Information
Important Safety Information
Cholinesterase inhibitors have the potential to increase gastric acid secretion.
Patients at risk for developing ulcers, including those receiving concurrent NSAIDs,
should be monitored closely for gastrointestinal bleeding.
In clinical trials, syncopal episodes have been reported (2% for ARICEPT versus
1% for placebo).
In clinical trials, the most common adverse events seen with ARICEPT were nausea,
diarrhea, insomnia, vomiting, muscle cramps, fatigue, anorexia, and ecchymosis.
In studies, these were usually mild and transient.